speb/financial-data huggingface dataset:
GENM.TO income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: -5312684.00
GENM.TO income_statement (quarterly, 2025-06-30) — Net Interest Income: -6685.00
GENM.TO cash_flow (quarterly, 2025-06-30) — Net Issuance Payments Of Debt: -205207.00
GENM.TO cash_flow (quarterly, 2025-06-30) — Net Long Term Debt Issuance: -205207.00
GENM.TO income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -6685.00
GENM.TO balance_sheet (quarterly, 2025-06-30) — Net PPE: 738890.00
GENM.TO cash_flow (quarterly, 2025-06-30) — Net PPE Purchase And Sale: 0.00
GENM.TO balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: -49304881.00
GENM.TO balance_sheet (quarterly, 2025-06-30) — Non Current Prepaid Assets: 80000.00
GENM.TO income_statement (quarterly, 2025-06-30) — Normalized EBITDA: -1914194.00
GENM.TO income_statement (quarterly, 2025-06-30) — Normalized Income: -2002408.00
GENM.TO cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: -1019142.00
GENM.TO cash_flow (quarterly, 2025-06-30) — Operating Gains Losses: -475036.00
GENM.TO income_statement (quarterly, 2025-06-30) — Operating Income: -2470759.00
GENM.TO income_statement (quarterly, 2025-06-30) — Operating Revenue: 0.00
GENM.TO balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 268185606.00
GENM.TO balance_sheet (quarterly, 2025-06-30) — Other Equity Adjustments: -2602649.00
GENM.TO balance_sheet (quarterly, 2025-06-30) — Other Equity Interest: 6065061.00
GENM.TO income_statement (quarterly, 2025-06-30) — Other Gand A: 323181.00
GENM.TO income_statement (quarterly, 2025-06-30) — Other Income Expense: -2835240.00
GENM.TO balance_sheet (quarterly, 2025-06-30) — Other Non Current Assets: 38229.00
GENM.TO income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 1366657.00
GENM.TO balance_sheet (quarterly, 2025-06-30) — Other Properties: 1081614.00
GENM.TO balance_sheet (quarterly, 2025-06-30) — Other Receivables: 1447.00
GENM.TO balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 1861837.00
GENM.TO balance_sheet (quarterly, 2025-06-30) — Prepaid Assets: 159939.00
GENM.TO income_statement (quarterly, 2025-06-30) — Pretax Income: -5312684.00
GENM.TO cash_flow (quarterly, 2025-06-30) — Purchase Of PPE: 0.00
GENM.TO balance_sheet (quarterly, 2025-06-30) — Receivables: 334884.00
GENM.TO income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 40392.00
GENM.TO income_statement (quarterly, 2025-06-30) — Rent And Landing Fees: 21645.00
GENM.TO income_statement (quarterly, 2025-06-30) — Rent Expense Supplemental: 21645.00
GENM.TO cash_flow (quarterly, 2025-06-30) — Repayment Of Debt: -205207.00
GENM.TO balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -141956120.00
GENM.TO income_statement (quarterly, 2025-06-30) — Salaries And Wages: 759276.00
GENM.TO income_statement (quarterly, 2025-06-30) — Selling General And Administration: 1104102.00
GENM.TO balance_sheet (quarterly, 2025-06-30) — Share Issued: 268185606.00
GENM.TO income_statement (quarterly, 2025-06-30) — Special Income Charges: 0.00
GENM.TO cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 759276.00
GENM.TO balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: -49304881.00
GENM.TO balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: -49304881.00
GENM.TO income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
GENM.TO income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.00
GENM.TO balance_sheet (quarterly, 2025-06-30) — Taxes Receivable: 78255.00
GENM.TO balance_sheet (quarterly, 2025-06-30) — Total Assets: 15324905.00
GENM.TO balance_sheet (quarterly, 2025-06-30) — Total Capitalization: -49304881.00
GENM.TO balance_sheet (quarterly, 2025-06-30) — Total Debt: 1204761.00
GENM.TO balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: -49304881.00
GENM.TO income_statement (quarterly, 2025-06-30) — Total Expenses: 2470759.00
GENM.TO balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 64629786.00
GENM.TO balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 1792765.00
GENM.TO balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 61563188.00
GENM.TO income_statement (quarterly, 2025-06-30) — Total Unusual Items: -3310276.00
GENM.TO income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: -3310276.00
GENM.TO cash_flow (quarterly, 2025-06-30) — Unrealized Gain Loss On Investment Securities: 3311649.00
GENM.TO balance_sheet (quarterly, 2025-06-30) — Working Capital: 10465542.00
GENM.TO income_statement (annual, 2025-12-31) — +Operating Expense: 9165697.00
GENM.TO income_statement (quarterly, 2025-12-31) — +Operating Expense: 2928925.00
GENM.TO income_statement (annual, 2025-12-31) — +Total Revenue: 0.00
GENM.TO income_statement (quarterly, 2025-12-31) — +Total Revenue: 0.00
GENM.TO balance_sheet (annual, 2025-12-31) — Accrued Interest Receivable: 116401.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Accrued Interest Receivable: 116401.00
GENM.TO balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -482076.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -482076.00
GENM.TO cash_flow (annual, 2025-12-31) — Asset Impairment Charge: 0.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Asset Impairment Charge: 0.00
GENM.TO income_statement (annual, 2025-12-31) — Basic Average Shares: 253608365.00
GENM.TO income_statement (annual, 2025-12-31) — Basic EPS: -0.13
GENM.TO cash_flow (annual, 2025-12-31) — Beginning Cash Position: 5525287.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 11547137.00
GENM.TO balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 1284893.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 1284893.00
GENM.TO balance_sheet (annual, 2025-12-31) — Capital Stock: 90364753.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Capital Stock: 90364753.00
GENM.TO balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 10036091.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 10036091.00
GENM.TO balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 10036091.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 10036091.00
GENM.TO cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: 10980352.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: 580190.00
GENM.TO cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: 0.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: 0.00
GENM.TO cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: -6469548.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: -2091236.00
GENM.TO cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: 750700.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: -39693.00
GENM.TO cash_flow (annual, 2025-12-31) — Change In Prepaid Assets: 20201.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: -73371.00
GENM.TO cash_flow (annual, 2025-12-31) — Change In Receivables: -67609.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Change In Receivables: -80900.00
GENM.TO cash_flow (annual, 2025-12-31) — Change In Working Capital: 703292.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Change In Working Capital: -193964.00
GENM.TO cash_flow (annual, 2025-12-31) — Changes In Cash: 4510804.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Changes In Cash: -1511046.00
GENM.TO balance_sheet (annual, 2025-12-31) — Common Stock: 90364753.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Common Stock: 90364753.00
GENM.TO balance_sheet (annual, 2025-12-31) — Common Stock Equity: -70219272.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: -70219272.00
GENM.TO cash_flow (annual, 2025-12-31) — Common Stock Issuance: 10754128.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Common Stock Issuance: 0.00
GENM.TO balance_sheet (annual, 2025-12-31) — Current Assets: 10559647.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Current Assets: 10559647.00
GENM.TO balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 1138053.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 1138053.00
GENM.TO balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 1138053.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 1138053.00
GENM.TO balance_sheet (annual, 2025-12-31) — Current Liabilities: 3305866.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 3305866.00
GENM.TO cash_flow (annual, 2025-12-31) — Depreciation: 185708.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Depreciation: 65099.00
GENM.TO cash_flow (annual, 2025-12-31) — Depreciation Amortization Depletion: 185708.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 65099.00
GENM.TO cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 185708.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 65099.00
GENM.TO balance_sheet (annual, 2025-12-31) — Derivative Product Liabilities: 79143812.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Derivative Product Liabilities: 79143812.00
GENM.TO income_statement (annual, 2025-12-31) — Diluted Average Shares: 253608365.00
GENM.TO income_statement (annual, 2025-12-31) — Diluted EPS: -0.13
GENM.TO income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: -33865514.00
GENM.TO income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: -15541458.00
GENM.TO income_statement (annual, 2025-12-31) — EBIT: -33686941.00
GENM.TO income_statement (quarterly, 2025-12-31) — EBIT: -15565035.00
GENM.TO income_statement (annual, 2025-12-31) — EBITDA: -33501233.00
GENM.TO income_statement (quarterly, 2025-12-31) — EBITDA: -15499936.00
GENM.TO income_statement (annual, 2025-12-31) — Earnings From Equity Interest: -623830.00
GENM.TO income_statement (quarterly, 2025-12-31) — Earnings From Equity Interest: 134952.00
GENM.TO cash_flow (annual, 2025-12-31) — Earnings Losses From Equity Investments: 623830.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Earnings Losses From Equity Investments: -134952.00
GENM.TO cash_flow (annual, 2025-12-31) — End Cash Position: 10036091.00
GENM.TO cash_flow (quarterly, 2025-12-31) — End Cash Position: 10036091.00
GENM.TO cash_flow (annual, 2025-12-31) — Financing Cash Flow: 10980352.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: 580190.00
GENM.TO cash_flow (annual, 2025-12-31) — Free Cash Flow: -6469548.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Free Cash Flow: -2091236.00
GENM.TO income_statement (annual, 2025-12-31) — Gain On Sale Of Security: -24039479.00
GENM.TO income_statement (quarterly, 2025-12-31) — Gain On Sale Of Security: -12771062.00
GENM.TO balance_sheet (annual, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: -2602649.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: -2602649.00
GENM.TO income_statement (annual, 2025-12-31) — General And Administrative Expense: 4597618.00
GENM.TO income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 1751525.00
GENM.TO balance_sheet (annual, 2025-12-31) — Gross PPE: 1400901.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Gross PPE: 1400901.00
GENM.TO income_statement (annual, 2025-12-31) — Interest Expense: 178573.00
GENM.TO income_statement (quarterly, 2025-12-31) — Interest Expense: -23577.00
GENM.TO income_statement (annual, 2025-12-31) — Interest Expense Non Operating: 178573.00
GENM.TO income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: -23577.00
GENM.TO balance_sheet (annual, 2025-12-31) — Invested Capital: -70219272.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Invested Capital: -70219272.00
GENM.TO cash_flow (annual, 2025-12-31) — Investing Cash Flow: 0.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: 0.00
GENM.TO balance_sheet (annual, 2025-12-31) — Investments And Advances: 780545.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Investments And Advances: 780545.00
GENM.TO balance_sheet (annual, 2025-12-31) — Investmentsin Associatesat Cost: 780545.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Investmentsin Associatesat Cost: 780545.00
GENM.TO cash_flow (annual, 2025-12-31) — Issuance Of Capital Stock: 10754128.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Issuance Of Capital Stock: 0.00
GENM.TO balance_sheet (annual, 2025-12-31) — Long Term Capital Lease Obligation: 146840.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Long Term Capital Lease Obligation: 146840.00
GENM.TO balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 146840.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 146840.00
GENM.TO cash_flow (annual, 2025-12-31) — Long Term Debt Payments: -462142.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Long Term Debt Payments: -36176.00
GENM.TO balance_sheet (annual, 2025-12-31) — Long Term Equity Investment: 780545.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Long Term Equity Investment: 780545.00
GENM.TO balance_sheet (annual, 2025-12-31) — Machinery Furniture Equipment: 92011.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Machinery Furniture Equipment: 92011.00
GENM.TO cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: 10754128.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Net Common Stock Issuance: 0.00
GENM.TO income_statement (annual, 2025-12-31) — Net Income: -33865514.00
GENM.TO income_statement (quarterly, 2025-12-31) — Net Income: -15541458.00
GENM.TO income_statement (annual, 2025-12-31) — Net Income Common Stockholders: -33865514.00
GENM.TO income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: -15541458.00
GENM.TO income_statement (annual, 2025-12-31) — Net Income Continuous Operations: -33865514.00
GENM.TO income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: -15541458.00
GENM.TO income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -33865514.00
GENM.TO income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -15541458.00
GENM.TO income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -33865514.00
GENM.TO income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -15541458.00
GENM.TO cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: -33865514.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: -15541458.00
GENM.TO income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: -33865514.00
GENM.TO income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: -15541458.00
GENM.TO income_statement (annual, 2025-12-31) — Net Interest Income: -178573.00
GENM.TO income_statement (quarterly, 2025-12-31) — Net Interest Income: 23577.00
GENM.TO cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: -462142.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Net Issuance Payments Of Debt: -36176.00
GENM.TO cash_flow (annual, 2025-12-31) — Net Long Term Debt Issuance: -462142.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Net Long Term Debt Issuance: -36176.00
GENM.TO income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: -178573.00
GENM.TO income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: 23577.00
GENM.TO balance_sheet (annual, 2025-12-31) — Net PPE: 918825.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Net PPE: 918825.00
GENM.TO cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: 0.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Net PPE Purchase And Sale: 0.00
GENM.TO balance_sheet (annual, 2025-12-31) — Net Tangible Assets: -70219272.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: -70219272.00
GENM.TO balance_sheet (annual, 2025-12-31) — Non Current Prepaid Assets: 80000.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Non Current Prepaid Assets: 80000.00
GENM.TO income_statement (annual, 2025-12-31) — Normalized EBITDA: -9603819.00
GENM.TO income_statement (quarterly, 2025-12-31) — Normalized EBITDA: -2728874.00
GENM.TO income_statement (annual, 2025-12-31) — Normalized Income: -9968100.00
GENM.TO income_statement (quarterly, 2025-12-31) — Normalized Income: -2770396.00
GENM.TO cash_flow (annual, 2025-12-31) — Operating Cash Flow: -6469548.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: -2091236.00
GENM.TO cash_flow (annual, 2025-12-31) — Operating Gains Losses: 623830.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Operating Gains Losses: -134952.00
GENM.TO income_statement (annual, 2025-12-31) — Operating Income: -9165697.00
GENM.TO income_statement (quarterly, 2025-12-31) — Operating Income: -2928925.00
GENM.TO income_statement (annual, 2025-12-31) — Operating Revenue: 0.00
GENM.TO income_statement (quarterly, 2025-12-31) — Operating Revenue: 0.00
GENM.TO balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 270343536.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 270343536.00
GENM.TO balance_sheet (annual, 2025-12-31) — Other Equity Adjustments: -2602649.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Other Equity Adjustments: -2602649.00
GENM.TO balance_sheet (annual, 2025-12-31) — Other Equity Interest: 6310338.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Other Equity Interest: 6310338.00
GENM.TO income_statement (annual, 2025-12-31) — Other Gand A: 2524815.00
GENM.TO income_statement (quarterly, 2025-12-31) — Other Gand A: 778785.00
GENM.TO income_statement (annual, 2025-12-31) — Other Income Expense: -24521244.00
GENM.TO income_statement (quarterly, 2025-12-31) — Other Income Expense: -12636110.00
GENM.TO cash_flow (annual, 2025-12-31) — Other Non Cash Items: -142065.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Other Non Cash Items: 0.00
GENM.TO balance_sheet (annual, 2025-12-31) — Other Non Current Assets: 38229.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Other Non Current Assets: 38229.00
GENM.TO income_statement (annual, 2025-12-31) — Other Operating Expenses: 4568079.00
GENM.TO income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 1177400.00
GENM.TO balance_sheet (annual, 2025-12-31) — Other Properties: 1308890.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Other Properties: 1308890.00
GENM.TO balance_sheet (annual, 2025-12-31) — Other Receivables: 1446.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Other Receivables: 1446.00
GENM.TO income_statement (annual, 2025-12-31) — Other Special Charges: -142065.00
GENM.TO income_statement (quarterly, 2025-12-31) — Other Special Charges: 0.00
GENM.TO balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 2167813.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 2167813.00
GENM.TO balance_sheet (annual, 2025-12-31) — Prepaid Assets: 201089.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Prepaid Assets: 201089.00
GENM.TO income_statement (annual, 2025-12-31) — Pretax Income: -33865514.00
GENM.TO income_statement (quarterly, 2025-12-31) — Pretax Income: -15541458.00
GENM.TO cash_flow (annual, 2025-12-31) — Proceeds From Stock Option Exercised: 688366.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Proceeds From Stock Option Exercised: 616366.00
GENM.TO cash_flow (annual, 2025-12-31) — Purchase Of PPE: 0.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Purchase Of PPE: 0.00
GENM.TO balance_sheet (annual, 2025-12-31) — Receivables: 322467.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Receivables: 322467.00
GENM.TO income_statement (annual, 2025-12-31) — Reconciled Depreciation: 185708.00
GENM.TO income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 65099.00
GENM.TO income_statement (annual, 2025-12-31) — Rent And Landing Fees: 88003.00
GENM.TO income_statement (quarterly, 2025-12-31) — Rent And Landing Fees: 31070.00
GENM.TO income_statement (annual, 2025-12-31) — Rent Expense Supplemental: 88003.00
GENM.TO income_statement (quarterly, 2025-12-31) — Rent Expense Supplemental: 31070.00
GENM.TO cash_flow (annual, 2025-12-31) — Repayment Of Debt: -462142.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Repayment Of Debt: -36176.00
GENM.TO balance_sheet (annual, 2025-12-31) — Retained Earnings: -164291714.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -164291714.00
GENM.TO income_statement (annual, 2025-12-31) — Salaries And Wages: 1984800.00
GENM.TO income_statement (quarterly, 2025-12-31) — Salaries And Wages: 941670.00
GENM.TO income_statement (annual, 2025-12-31) — Selling General And Administration: 4597618.00
GENM.TO income_statement (quarterly, 2025-12-31) — Selling General And Administration: 1751525.00
GENM.TO balance_sheet (annual, 2025-12-31) — Share Issued: 270343536.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Share Issued: 270343536.00
GENM.TO income_statement (annual, 2025-12-31) — Special Income Charges: 142065.00
GENM.TO income_statement (quarterly, 2025-12-31) — Special Income Charges: 0.00
GENM.TO cash_flow (annual, 2025-12-31) — Stock Based Compensation: 1984800.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 941670.00
GENM.TO balance_sheet (annual, 2025-12-31) — Stockholders Equity: -70219272.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: -70219272.00
GENM.TO balance_sheet (annual, 2025-12-31) — Tangible Book Value: -70219272.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: -70219272.00
GENM.TO income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
GENM.TO income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
GENM.TO income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.00
GENM.TO income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.00
GENM.TO balance_sheet (annual, 2025-12-31) — Taxes Receivable: 204620.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Taxes Receivable: 204620.00
GENM.TO balance_sheet (annual, 2025-12-31) — Total Assets: 12377246.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Total Assets: 12377246.00
GENM.TO balance_sheet (annual, 2025-12-31) — Total Capitalization: -70219272.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Total Capitalization: -70219272.00
GENM.TO balance_sheet (annual, 2025-12-31) — Total Debt: 1284893.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Total Debt: 1284893.00
GENM.TO balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: -70219272.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: -70219272.00
GENM.TO income_statement (annual, 2025-12-31) — Total Expenses: 9165697.00
GENM.TO income_statement (quarterly, 2025-12-31) — Total Expenses: 2928925.00
GENM.TO balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 82596518.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 82596518.00
GENM.TO balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 1817599.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 1817599.00
GENM.TO balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 79290652.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 79290652.00
GENM.TO income_statement (annual, 2025-12-31) — Total Unusual Items: -23897414.00
GENM.TO income_statement (quarterly, 2025-12-31) — Total Unusual Items: -12771062.00
GENM.TO income_statement (annual, 2025-12-31) — Total Unusual Items Excluding Goodwill: -23897414.00
GENM.TO income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -12771062.00
GENM.TO cash_flow (annual, 2025-12-31) — Unrealized Gain Loss On Investment Securities: 24040401.00
GENM.TO cash_flow (quarterly, 2025-12-31) — Unrealized Gain Loss On Investment Securities: 12772369.00
GENM.TO balance_sheet (annual, 2025-12-31) — Working Capital: 7253781.00
GENM.TO balance_sheet (quarterly, 2025-12-31) — Working Capital: 7253781.00
GENM.TO income_statement (quarterly, 2026-03-31) — +Operating Expense: 5264443.00
GENM.TO income_statement (quarterly, 2026-03-31) — +Total Revenue: 0.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Accrued Interest Receivable: 286838.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -502956.00
GENM.TO income_statement (quarterly, 2026-03-31) — Basic Average Shares: 280676219.00
GENM.TO income_statement (quarterly, 2026-03-31) — Basic EPS: -0.06
GENM.TO cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 10036091.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 1301418.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Capital Stock: 116382442.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 40142743.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 40142743.00
GENM.TO cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: 33682006.00
GENM.TO cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: -3575354.00
GENM.TO cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: 1216266.00
GENM.TO cash_flow (quarterly, 2026-03-31) — Change In Prepaid Assets: -143340.00
GENM.TO cash_flow (quarterly, 2026-03-31) — Change In Receivables: -191057.00
GENM.TO cash_flow (quarterly, 2026-03-31) — Change In Working Capital: 881869.00
GENM.TO cash_flow (quarterly, 2026-03-31) — Changes In Cash: 30106652.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Common Stock: 116382442.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: -53000358.00
GENM.TO cash_flow (quarterly, 2026-03-31) — Common Stock Issuance: 32955367.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Current Assets: 41000696.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 1178971.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 1178971.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 4563050.00
GENM.TO cash_flow (quarterly, 2026-03-31) — Depreciation: 58166.00
GENM.TO cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 58166.00
GENM.TO cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 58166.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Derivative Product Liabilities: 91827753.00
GENM.TO income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 280676219.00
GENM.TO income_statement (quarterly, 2026-03-31) — Diluted EPS: -0.06
GENM.TO income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -17095953.00
GENM.TO income_statement (quarterly, 2026-03-31) — EBIT: -17050328.00
GENM.TO income_statement (quarterly, 2026-03-31) — EBITDA: -16992162.00
GENM.TO income_statement (quarterly, 2026-03-31) — Earnings From Equity Interest: 712867.00
GENM.TO cash_flow (quarterly, 2026-03-31) — Earnings Losses From Equity Investments: 64017.00
GENM.TO cash_flow (quarterly, 2026-03-31) — End Cash Position: 40142743.00
GENM.TO cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: 33682006.00
GENM.TO cash_flow (quarterly, 2026-03-31) — Free Cash Flow: -3575354.00
GENM.TO income_statement (quarterly, 2026-03-31) — Gain On Sale Of Security: -12685453.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Gains Losses Not Affecting Retained Earnings: -2602649.00
GENM.TO income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 2636449.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Gross PPE: 1403511.00
GENM.TO income_statement (quarterly, 2026-03-31) — Interest Expense: 45625.00
GENM.TO income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 45625.00
GENM.TO income_statement (quarterly, 2026-03-31) — Interest Income: 186701.00
GENM.TO income_statement (quarterly, 2026-03-31) — Interest Income Non Operating: 186701.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Invested Capital: -53000358.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Investments And Advances: 1493412.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Investmentsin Associatesat Cost: 1493412.00
GENM.TO cash_flow (quarterly, 2026-03-31) — Issuance Of Capital Stock: 32955367.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 122447.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 122447.00
GENM.TO cash_flow (quarterly, 2026-03-31) — Long Term Debt Payments: -23371.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Long Term Equity Investment: 1493412.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Machinery Furniture Equipment: 92011.00
GENM.TO cash_flow (quarterly, 2026-03-31) — Net Common Stock Issuance: 32955367.00
GENM.TO income_statement (quarterly, 2026-03-31) — Net Income: -17095953.00
GENM.TO income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -17095953.00
GENM.TO income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -17095953.00
GENM.TO income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -17095953.00
GENM.TO income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -17095953.00
GENM.TO cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: -17095953.00
GENM.TO income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -17095953.00
GENM.TO income_statement (quarterly, 2026-03-31) — Net Interest Income: 141076.00
GENM.TO cash_flow (quarterly, 2026-03-31) — Net Issuance Payments Of Debt: -23371.00
GENM.TO cash_flow (quarterly, 2026-03-31) — Net Long Term Debt Issuance: -23371.00
GENM.TO income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: 141076.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Net PPE: 900555.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: -53000358.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Non Current Prepaid Assets: 80000.00
GENM.TO income_statement (quarterly, 2026-03-31) — Normalized EBITDA: -4306709.00
GENM.TO income_statement (quarterly, 2026-03-31) — Normalized Income: -4410500.00
GENM.TO cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: -3575354.00
GENM.TO cash_flow (quarterly, 2026-03-31) — Operating Gains Losses: 64017.00
GENM.TO income_statement (quarterly, 2026-03-31) — Operating Income: -5264443.00
GENM.TO income_statement (quarterly, 2026-03-31) — Operating Revenue: 0.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 321129850.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Other Equity Adjustments: -2602649.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 14607516.00
GENM.TO income_statement (quarterly, 2026-03-31) — Other Gand A: 1986174.00
GENM.TO income_statement (quarterly, 2026-03-31) — Other Income Expense: -11972586.00
GENM.TO cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: -776884.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 38229.00
GENM.TO income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 2627994.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Other Properties: 1311500.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Other Receivables: 1446.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 3384079.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 344429.00
GENM.TO income_statement (quarterly, 2026-03-31) — Pretax Income: -17095953.00
GENM.TO cash_flow (quarterly, 2026-03-31) — Proceeds From Stock Option Exercised: 750010.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Receivables: 513524.00
GENM.TO income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 58166.00
GENM.TO income_statement (quarterly, 2026-03-31) — Rent And Landing Fees: 40785.00
GENM.TO income_statement (quarterly, 2026-03-31) — Rent Expense Supplemental: 40785.00
GENM.TO cash_flow (quarterly, 2026-03-31) — Repayment Of Debt: -23371.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Retained Earnings: -181387667.00
GENM.TO income_statement (quarterly, 2026-03-31) — Salaries And Wages: 609490.00
GENM.TO income_statement (quarterly, 2026-03-31) — Selling General And Administration: 2636449.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Share Issued: 321129850.00
GENM.TO cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 609490.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: -53000358.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: -53000358.00
GENM.TO income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
GENM.TO income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: 225240.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Total Assets: 43512892.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Total Capitalization: -53000358.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Total Debt: 1301418.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: -53000358.00
GENM.TO income_statement (quarterly, 2026-03-31) — Total Expenses: 5264443.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 96513250.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 2512196.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 91950200.00
GENM.TO income_statement (quarterly, 2026-03-31) — Total Unusual Items: -12685453.00
GENM.TO income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: -12685453.00
GENM.TO cash_flow (quarterly, 2026-03-31) — Unrealized Gain Loss On Investment Securities: 12683941.00
GENM.TO balance_sheet (quarterly, 2026-03-31) — Working Capital: 36437646.00
GENO.OL income_statement (annual, 2023-12-31) — +Operating Expense: 489923000.00
GENO.OL income_statement (annual, 2023-12-31) — +Total Revenue: 808769000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Accounts Payable: 114826000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Accounts Receivable: 153401000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Additional Paid In Capital: 535115000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Available For Sale Securities: 3379000.00
GENO.OL income_statement (annual, 2023-12-31) — Basic Average Shares: 192245306.00
GENO.OL income_statement (annual, 2023-12-31) — Basic EPS: -0.38
GENO.OL cash_flow (annual, 2023-12-31) — Beginning Cash Position: 153824000.00
GENO.OL cash_flow (annual, 2023-12-31) — Capital Expenditure: -30974000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 80423000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Capital Stock: 5570000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 172652000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 172652000.00
GENO.OL cash_flow (annual, 2023-12-31) — Cash Dividends Paid: -25000000.00
GENO.OL cash_flow (annual, 2023-12-31) — Change In Inventory: -37664000.00
GENO.OL cash_flow (annual, 2023-12-31) — Change In Other Current Assets: -68000.00
GENO.OL cash_flow (annual, 2023-12-31) — Change In Other Current Liabilities: 0.00
GENO.OL cash_flow (annual, 2023-12-31) — Change In Payable: -28006000.00
GENO.OL cash_flow (annual, 2023-12-31) — Change In Receivables: 23597000.00
GENO.OL cash_flow (annual, 2023-12-31) — Change In Working Capital: -42141000.00
GENO.OL cash_flow (annual, 2023-12-31) — Changes In Cash: 9374000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Common Stock: 5570000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Common Stock Equity: 625280000.00
GENO.OL cash_flow (annual, 2023-12-31) — Common Stock Issuance: 209972000.00
GENO.OL income_statement (annual, 2023-12-31) — Cost Of Revenue: 247986000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Current Assets: 535872000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 13236000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Current Debt: 14065000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Current Debt And Capital Lease Obligation: 27301000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Current Liabilities: 181081000.00
GENO.OL cash_flow (annual, 2023-12-31) — Deferred Tax: 17039000.00
GENO.OL cash_flow (annual, 2023-12-31) — Depreciation: 50149000.00
GENO.OL cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 50149000.00
GENO.OL income_statement (annual, 2023-12-31) — Depreciation And Amortization In Income Statement: 49047000.00
GENO.OL income_statement (annual, 2023-12-31) — Depreciation Income Statement: 49047000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Derivative Product Liabilities: 2058000.00
GENO.OL income_statement (annual, 2023-12-31) — Diluted Average Shares: 192245306.00
GENO.OL income_statement (annual, 2023-12-31) — Diluted EPS: -0.38
GENO.OL income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: -72525000.00
GENO.OL income_statement (annual, 2023-12-31) — EBIT: -19619000.00
GENO.OL income_statement (annual, 2023-12-31) — EBITDA: 30530000.00
GENO.OL cash_flow (annual, 2023-12-31) — Effect Of Exchange Rate Changes: 9454000.00
GENO.OL cash_flow (annual, 2023-12-31) — End Cash Position: 172652000.00
GENO.OL cash_flow (annual, 2023-12-31) — Financing Cash Flow: 110301000.00
GENO.OL cash_flow (annual, 2023-12-31) — Free Cash Flow: 16762000.00
GENO.OL cash_flow (annual, 2023-12-31) — Gain Loss On Sale Of PPE: 150000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Goodwill: 0.00
GENO.OL balance_sheet (annual, 2023-12-31) — Goodwill And Other Intangible Assets: 252006000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Gross PPE: 235259000.00
GENO.OL income_statement (annual, 2023-12-31) — Gross Profit: 560783000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Hedging Assets Current: 3569000.00
GENO.OL income_statement (annual, 2023-12-31) — Interest Expense: 35867000.00
GENO.OL income_statement (annual, 2023-12-31) — Interest Expense Non Operating: 35867000.00
GENO.OL income_statement (annual, 2023-12-31) — Interest Income: 23025000.00
GENO.OL income_statement (annual, 2023-12-31) — Interest Income Non Operating: 23025000.00
GENO.OL cash_flow (annual, 2023-12-31) — Interest Paid Cfo: -16484000.00
GENO.OL cash_flow (annual, 2023-12-31) — Interest Received Cfi: 3465000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Inventory: 205744000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Invested Capital: 765825000.00
GENO.OL cash_flow (annual, 2023-12-31) — Investing Cash Flow: -148663000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Investmentin Financial Assets: 3379000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Investmentsin Associatesat Cost: 273000.00
GENO.OL cash_flow (annual, 2023-12-31) — Issuance Of Capital Stock: 209972000.00
GENO.OL cash_flow (annual, 2023-12-31) — Issuance Of Debt: 172965000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Long Term Capital Lease Obligation: 67187000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Long Term Debt: 126480000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 193667000.00
GENO.OL cash_flow (annual, 2023-12-31) — Long Term Debt Issuance: 172965000.00
GENO.OL cash_flow (annual, 2023-12-31) — Long Term Debt Payments: -233062000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Long Term Equity Investment: 273000.00
GENO.OL cash_flow (annual, 2023-12-31) — Net Business Purchase And Sale: -124707000.00
GENO.OL cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: 209972000.00
GENO.OL income_statement (annual, 2023-12-31) — Net Income: -72525000.00
GENO.OL income_statement (annual, 2023-12-31) — Net Income Common Stockholders: -72525000.00
GENO.OL income_statement (annual, 2023-12-31) — Net Income Continuous Operations: -72525000.00
GENO.OL income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: -72525000.00
GENO.OL income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: -72525000.00
GENO.OL cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: -72525000.00
GENO.OL income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: -72525000.00
GENO.OL cash_flow (annual, 2023-12-31) — Net Intangibles Purchase And Sale: -7065000.00
GENO.OL income_statement (annual, 2023-12-31) — Net Interest Income: -12842000.00
GENO.OL cash_flow (annual, 2023-12-31) — Net Issuance Payments Of Debt: -60097000.00
GENO.OL cash_flow (annual, 2023-12-31) — Net Long Term Debt Issuance: -60097000.00
GENO.OL income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: -12842000.00
GENO.OL cash_flow (annual, 2023-12-31) — Net Other Investing Changes: 3553000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Net PPE: 235259000.00
GENO.OL cash_flow (annual, 2023-12-31) — Net PPE Purchase And Sale: -23909000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Net Tangible Assets: 373274000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Non Current Deferred Revenue: 644000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Non Current Deferred Taxes Assets: 7362000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Non Current Deferred Taxes Liabilities: 43748000.00
GENO.OL income_statement (annual, 2023-12-31) — Normalized EBITDA: 30530000.00
GENO.OL income_statement (annual, 2023-12-31) — Normalized Income: 136306380.00
GENO.OL cash_flow (annual, 2023-12-31) — Operating Cash Flow: 47736000.00
GENO.OL income_statement (annual, 2023-12-31) — Operating Income: 70860000.00
GENO.OL income_statement (annual, 2023-12-31) — Operating Revenue: 808769000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 192245306.00
GENO.OL balance_sheet (annual, 2023-12-31) — Other Intangible Assets: 252006000.00
GENO.OL cash_flow (annual, 2023-12-31) — Other Non Cash Items: 12842000.00
GENO.OL income_statement (annual, 2023-12-31) — Other Non Operating Income Expenses: 7209000.00
GENO.OL income_statement (annual, 2023-12-31) — Other Operating Expenses: 162762000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Other Properties: 235259000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Other Receivables: 506000.00
GENO.OL income_statement (annual, 2023-12-31) — Otherunder Preferred Stock Dividend: 0.00
GENO.OL balance_sheet (annual, 2023-12-31) — Payables: 132798000.00
GENO.OL income_statement (annual, 2023-12-31) — Pretax Income: -55486000.00
GENO.OL cash_flow (annual, 2023-12-31) — Provisionand Write Offof Assets: 21000.00
GENO.OL cash_flow (annual, 2023-12-31) — Purchase Of Business: -124707000.00
GENO.OL cash_flow (annual, 2023-12-31) — Purchase Of Intangibles: -7065000.00
GENO.OL cash_flow (annual, 2023-12-31) — Purchase Of PPE: -23909000.00
GENO.OL income_statement (annual, 2023-12-31) — Reconciled Cost Of Revenue: 247986000.00
GENO.OL income_statement (annual, 2023-12-31) — Reconciled Depreciation: 50149000.00
GENO.OL cash_flow (annual, 2023-12-31) — Repayment Of Debt: -233062000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Retained Earnings: 21218000.00
GENO.OL cash_flow (annual, 2023-12-31) — Sale Of PPE: 3553000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Share Issued: 192245306.00
GENO.OL income_statement (annual, 2023-12-31) — Special Income Charges: -117321000.00
GENO.OL cash_flow (annual, 2023-12-31) — Stock Based Compensation: 0.00
GENO.OL balance_sheet (annual, 2023-12-31) — Stockholders Equity: 625280000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Tangible Book Value: 373274000.00
GENO.OL income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: -25810620.00
GENO.OL income_statement (annual, 2023-12-31) — Tax Provision: 17039000.00
GENO.OL income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.22
GENO.OL cash_flow (annual, 2023-12-31) — Taxes Refund Paid: -22028000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Total Assets: 1046478000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Total Capitalization: 751760000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Total Debt: 220968000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 625280000.00
GENO.OL income_statement (annual, 2023-12-31) — Total Expenses: 737909000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 421198000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 510606000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 240117000.00
GENO.OL income_statement (annual, 2023-12-31) — Total Operating Income As Reported: -39252000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Total Tax Payable: 17972000.00
GENO.OL income_statement (annual, 2023-12-31) — Total Unusual Items: 0.00
GENO.OL income_statement (annual, 2023-12-31) — Total Unusual Items Excluding Goodwill: -117321000.00
GENO.OL balance_sheet (annual, 2023-12-31) — Treasury Stock: 0.00
GENO.OL balance_sheet (annual, 2023-12-31) — Working Capital: 354791000.00
GENO.OL income_statement (annual, 2024-12-31) — +Operating Expense: 573488000.00
GENO.OL income_statement (annual, 2024-12-31) — +Total Revenue: 957068000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Accounts Payable: 130658000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Accounts Receivable: 188412000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 549127000.00
GENO.OL income_statement (annual, 2024-12-31) — Basic Average Shares: 192245306.00
GENO.OL income_statement (annual, 2024-12-31) — Basic EPS: 0.20
GENO.OL cash_flow (annual, 2024-12-31) — Beginning Cash Position: 172652000.00
GENO.OL cash_flow (annual, 2024-12-31) — Capital Expenditure: -17887000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 92400000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Capital Stock: 5615000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 281632000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 281632000.00
GENO.OL cash_flow (annual, 2024-12-31) — Cash Dividends Paid: -10000000.00
GENO.OL cash_flow (annual, 2024-12-31) — Change In Inventory: -26888000.00
GENO.OL cash_flow (annual, 2024-12-31) — Change In Other Current Assets: 75261000.00
GENO.OL cash_flow (annual, 2024-12-31) — Change In Other Current Liabilities: 0.00
GENO.OL cash_flow (annual, 2024-12-31) — Change In Payable: -13694000.00
GENO.OL cash_flow (annual, 2024-12-31) — Change In Receivables: 7838000.00
GENO.OL cash_flow (annual, 2024-12-31) — Change In Working Capital: 42517000.00
GENO.OL cash_flow (annual, 2024-12-31) — Changes In Cash: 102742000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Common Stock: 5615000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Common Stock Equity: 718389000.00
GENO.OL cash_flow (annual, 2024-12-31) — Common Stock Issuance: 0.00
GENO.OL income_statement (annual, 2024-12-31) — Cost Of Revenue: 319815000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Current Assets: 708365000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Current Capital Lease Obligation: 15118000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Current Debt: 144424000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Current Debt And Capital Lease Obligation: 159542000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Current Liabilities: 426390000.00
GENO.OL cash_flow (annual, 2024-12-31) — Deferred Tax: 21475000.00
GENO.OL cash_flow (annual, 2024-12-31) — Depreciation: 60197000.00
GENO.OL cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 60197000.00
GENO.OL income_statement (annual, 2024-12-31) — Depreciation And Amortization In Income Statement: 59385000.00
GENO.OL income_statement (annual, 2024-12-31) — Depreciation Income Statement: 59385000.00